
Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Cabaletta Bio in a research report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($1.26) for the year, up from their prior estimate of ($1.35). HC Wainwright currently has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.53) EPS.
CABA has been the topic of several other reports. Wells Fargo & Company dropped their target price on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen upgraded Cabaletta Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. William Blair upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Citigroup dropped their price target on shares of Cabaletta Bio to $8.00 and set a “buy” rating on the stock in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.33.
Cabaletta Bio Price Performance
Cabaletta Bio stock opened at $1.45 on Tuesday. The company has a market capitalization of $245.84 million, a P/E ratio of -1.03 and a beta of 3.56. The stock’s 50 day moving average is $2.02 and its 200 day moving average is $2.80. Cabaletta Bio has a twelve month low of $1.18 and a twelve month high of $4.23.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04.
Institutional Trading of Cabaletta Bio
A number of institutional investors and hedge funds have recently modified their holdings of CABA. BlackRock Inc. bought a new position in shares of Cabaletta Bio during the second quarter valued at $33,447,000. Jennison Associates LLC boosted its holdings in shares of Cabaletta Bio by 0.7% during the 1st quarter. Jennison Associates LLC now owns 8,970,578 shares of the company’s stock valued at $24,131,000 after acquiring an additional 64,879 shares during the last quarter. Opaleye Management Inc. boosted its holdings in shares of Cabaletta Bio by 180.0% during the 2nd quarter. Opaleye Management Inc. now owns 3,863,800 shares of the company’s stock valued at $12,016,000 after acquiring an additional 2,483,800 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Cabaletta Bio by 33.8% during the 1st quarter. Renaissance Technologies LLC now owns 2,036,663 shares of the company’s stock valued at $5,479,000 after acquiring an additional 514,080 shares during the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in shares of Cabaletta Bio in the second quarter worth approximately $2,852,181.
Top Cabaletta Bio Stories
These are some of the CABA stories that stood out recently:
- Positive Sentiment: HC Wainwright raised its EPS estimates across multiple periods, including FY2026 from a loss of $1.35 to $1.26 per share and FY2027 from $1.29 to $1.02 per share. The firm maintained its Buy rating and $16 target, a potentially supportive outlook, although Cabaletta is still expected to report losses.
- Positive Sentiment: Cabaletta presented new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026. Further evidence on the experimental therapy could influence investor expectations, but the provided report does not detail the results. Article: Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data At ACR Convergence 2026
- Negative Sentiment: Citigroup cut its price target for CABA, signaling a less favorable valuation view. The report provided here does not state the revised target. Article: Cabaletta Bio Stock Price Target Cut by Citigroup
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for people with autoimmune diseases. The company’s approach aims to address disease-causing immune cells while limiting disruption to the broader immune system. Its lead program, CABA-201, is an investigational CD19-directed CAR T-cell therapy being studied across several autoimmune conditions. Cabaletta is also developing DSG3-CAART, an engineered cell therapy designed to target B cells that produce antibodies associated with pemphigus vulgaris.
Featured Stories
- Five stocks we like better than Cabaletta Bio
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.
